What do I need to know about immunoglobulin light chain (AL) amyloidosis?

Blood Reviews

Volumn 26, Issue 4, 2012, Pages 137-154

  Dispenzieri, Angela ^a   Gertz, Morie A ^a   Buadi, Francis ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Monoclonal gammopathy; Multisystem disease; Prognosis; Transplantation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; PROTEIN PRECURSOR; THALIDOMIDE; VINCRISTINE;

AMYLOIDOSIS; ARTICLE; DELAYED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; FUNCTIONAL STATUS; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY; TREATMENT RESPONSE; TROPISM;

AMYLOIDOSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; PROGNOSIS;

EID: 84861480962     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.03.001     Document Type: Article

References (197)

1. Kyle R.A., Linos A., Beard C.M., et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992, 79(7):1817-1822.
2. Sipe J.D., Benson M.D., Buxbaum J.N., et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010, 17(3-4):101-104. Prepublished on 2010/11/03 as DOI 10.3109/13506129.2010.526812.
3. Vrana J.A., Gamez J.D., Madden B.J., Theis J.D., Bergen H.R., Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood 2009, 114:4957-4959.
4. Desikan K.R., Dhodapkar M.V., Hough A., et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997, 27(3-4):315-319.
5. Madan S., Dispenzieri A., Lacy M.Q., et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010, 85(3):232-238.
6. Perfetti V., Casarini S., Palladini G., et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 2002, 100(3):948-953.
7. Stevens F.J., Weiss D.T., Solomon A. Structural bases of light chain related pathology. The Antibodies 1999, vol. 5:175-208. Harwood Academic Publishers, Amsterdam. M. Zanetti, J.D. Capra (Eds.).
8. Stevenson F., Sahota S., Zhu D., et al. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunol Rev 1998, 162:247-259. Prepublished on 1998/05/29 as DOI.
9. Hurle M.R., Helms L.R., Li L., Chan W., Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 1994, 91(12):5446-5450.
10. Stevens P.W., Raffen R., Hanson D.K., et al. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci 1995, 4(3):421-432. Prepublished on 1995/03/01 as DOI 10.1002/pro.5560040309.
11. Connors L.H., Jiang Y., Budnik M., et al. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kapp a1 immunoglobulin light chains. Biochemistry 2007, 46(49):14259-14271.
12. Randles E.G., Thompson J.R., Martin D.J., Ramirez-Alvarado M. Structural alterations within native amyloidogenic immunoglobulin light chains. J Mol Biol 2009, 389(1):199-210.
13. Poshusta T.L., Sikkink L.A., Leung N., Clark R.J., Dispenzieri A., Ramirez-Alvarado M. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with Al amyloidosis. PLoS One 2009, 4(4):e5169.
14. Shirahama T., Benson M.D., Cohen A.S., Tanaka A. Fibrillar assemblage of variable segments of immunoglobulin light chains: an electron microscopic study. J Immunol 1973, 110(1):21-30. Prepublished on 1973/01/01 as DOI.
15. Shirahama T., Cohen A.S. Intralysosomal formation of amyloid fibrils. Am J Pathol 1975, 81(1):101-116. Prepublished on 1975/10/01 as DOI.
16. Teng J., Russell W.J., Gu X., Cardelli J., Jones M.L., Herrera G.A. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004, 84(4):440-451. Prepublished on 2004/03/03 as DOI 10.1038/labinvest.3700069.
17. Keeling J., Teng J., Herrera G.A. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004, 84(10):1322-1338. Prepublished on 2004/08/03 as DOI 10.1038/labinvest.3700161.
18. Sakata N., Hoshii Y., Nakamura T., et al. Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem 2005, 53(2):237-242.
19. Comenzo R.L., Wally J., Kica G., et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol 1999, 106(3):744-751.
20. Comenzo R.L., Zhang Y., Martinez C., Osman K., Herrera G.A. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001, 98(3):714-720. Prepublished on 2001/07/27 as DOI.
21. Abraham R.S., Geyer S.M., Price-Troska T.L., et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003, 101(10):3801-3808. Prepublished on 2003/01/08 as DOI 10.1182/blood-2002-09-2707 2002-09-2707 [pii].
22. Prokaeva T., Spencer B., Kaut M., et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007, 56(11):3858-3868.
23. Bellavia D., Abraham R.S., Pellikka P.A., et al. Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al). J Am Soc Echocardiogr 2011, 24(4):444-454. Prepublished on 2011/02/15 as DOI 10.1016/j.echo.2011.01.003.
24. Gertz M.A., Kyle R.A. Primary systemic amyloidosis-a diagnostic primer. Mayo Clin Proc 1989, 64(12):1505-1519.
25. Palladini G., Kyle R.A., Larson D.R., Therneau T.M., Merlini G., Gertz M.A. Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid 2005, 12(2):120-126.
26. Katzmann J.A., Kyle R.A., Benson J., et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009, 55(8):1517-1522.
27. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995, 32(1):45-59.
28. Lachmann H.J., Booth D.R., Booth S.E., et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002, 346(23):1786-1791.
29. Comenzo R.L., Zhou P., Fleisher M., Clark B., Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006, 107(9):3489-3491.
30. Vrana J.A., Gamez J.D., Madden B.J., Theis J.D., Bergen H.R., Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood 2009, 114:4957-4959.
31. Brambilla F., Lavatelli F., Di Silvestre D., et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2011, 119:1844-1847.
32. Gertz M.A., Lacy M.Q., Dispenzieri A., Hayman S.R. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 2005, 6(3):208-219.
33. Biewend M.L., Menke D.M., Calamia K.T. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid 2006, 13(3):135-142. Prepublished on 2006/10/26 as DOI 10.1080/13506120600876773.
34. Hamidi Asl K., Liepnieks J.J., Nakamura M., Benson M.D. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 1999, 162(9):5556-5560.
35. Paccalin M., Hachulla E., Cazalet C., et al. Localized amyloidosis: a survey of 35 French cases. Amyloid 2005, 12(4):239-245.
36. Kristen A.V., Giannitsis E., Lehrke S., et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010, 116(14):2455-2461.
37. Perlini S., Musca F., Salinaro F., et al. Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid 2011, 18(Suppl. 1):91-92. Prepublished on 2011/08/16 as DOI 10.3109/13506129.2011.574354035.
38. Klein A.L., Hatle L.K., Taliercio C.P., et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991, 83(3):808-816.
39. Cueto-Garcia L., Reeder G.S., Kyle R.A., et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985, 6(4):737-743.
40. Oh J.K., Tajik A.J., Edwards W.D., Bresnahan J.F., Kyle R.A. Dynamic left ventricular outflow tract obstruction in cardiac amyloidosis detected by continuous-wave Doppler echocardiography. Am J Cardiol 1987, 59(9):1008-1010.
41. Klein A.L., Hatle L.K., Burstow D.J., et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990, 15(1):99-108.
42. Ghio S., Perlini S., Palladini G., et al. Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 2007, 9(8):808-813.
43. Patel A.R., Dubrey S.W., Mendes L.A., et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997, 80(4):486-492.
44. Modesto K.M., Dispenzieri A., Cauduro S.A., et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J 2005, 26(2):173-179.
45. Koyama J., Ray-Sequin P.A., Falk R.H. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003, 107(19):2446-2452.
46. Bellavia D., Abraham T.P., Pellikka P.A., et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 2007, 20(10):1194-1202.
47. Bellavia D., Pellikka P.A., Abraham T.P., et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008, 101(7):1039-1045.
48. Bellavia D., Pellikka P.A., Abraham T.P., et al. 'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis. Heart 2009, 95(3):234-240.
49. Maceira A.M., Prasad S.K., Hawkins P.N., Roughton M., Pennell D.J. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008, 10(1):54.
50. Ruberg F.L., Appelbaum E., Davidoff R., et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009, 103(4):544-549.
51. Palladini G., Malamani G., Co F., et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001, 24(8 Pt 1):1228-1233.
52. Kyle R.A., Greipp P.R., O'Fallon W.M. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986, 68(1):220-224.
53. Kumar S.K., Gertz M.A., Lacy M.Q., et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011, 86(1):12-18. Prepublished on 2011/01/05 as DOI 86/1/12 [pii] 4065/mcp. 2010.0480.
54. Dispenzieri A., Gertz M.A., Kyle R.A., et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004, 104(6):1881-1887.
55. Dispenzieri A., Gertz M.A., Kyle R.A., et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004, 22(18):3751-3757.
56. Palladini G., Campana C., Klersy C., et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003, 107(19):2440-2445.
57. Dispenzieri A., Kyle R.A., Gertz M.A., et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003, 361(9371):1787-1789.
58. Palladini G., Lavatelli F., Russo P., et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006, 107(10):3854-3858.
59. Lebovic D., Hoffman J., Levine B.M., et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008, 143(3):369-373.
60. Palladini G., Barassi A., Klersy C., et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010, 116(18):3426-3430.
61. Dispenzieri A., Gertz M.A., Saenger A.K., et al. The utility of high sensitivity cardiac troponin among patients with immunoglobulin light chain amyloidosis. Blood 2011, 118(11):2887-
62. Jaffe A.S. The 10 commandments of troponin, with special reference to high sensitivity assays. Heart 2011, 97(11):940-946. Prepublished on 2011/05/12 as DOI 10.1136/hrt.2009.185751.
63. Park H.J., Baek S.H., Jang S.W., et al. Direct comparison of B-type natriuretic peptide and N-terminal pro-BNP for assessment of cardiac function in a large population of symptomatic patients. Int J Cardiol 2010, 140(3):336-343. Prepublished on 2009/01/17 as DOI 10.1016/j.ijcard.2008.11.107.
64. Tagore R., Ling L.H., Yang H., Daw H.Y., Chan Y.H., Sethi S.K. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3(6):1644-1651. Prepublished on 2008/07/18 as DOI 10.2215/CJN.00850208.
65. Gertz M.A., Kyle R.A. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 1994, 24(2):124-138.
66. Gertz M.A., Lacy M.Q., Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 1999, 74(5):490-494.
67. Kyle R.A., Bayrd E.D. Amyloidosis: review of 236 cases. Medicine 1975, 54(4):271-299.
68. Gertz M.A., Kyle R.A., Greipp P.R. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood 1989, 74(3):1108-1111.
69. Kyle R.A., Greipp P.R. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983, 58(10):665-683.
70. Gertz M.A., Kyle R.A. Prognostic value of urinary protein in primary systemic amyloidosis (AL). Am J Clin Pathol 1990, 94(3):313-317.
71. Dispenzieri A., Lacy M.Q., Katzmann J.A., et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006, 107(8):3378-3383.
72. Wechalekar A.D., Wassef N.L., Gibbs S.D.J., et al. A new staging system for AL amyloidosis incorporating serum free light chains, cardiac troponin-T and NT-ProBNP. ASH Annu Meet Abstr 2009, 114(22):2796.
73. Kumar S., Dispenzieri A., Katzmann J.A., et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010, 116(24):5126-5129. Prepublished on 2010/08/28 as DOI 10.1182/blood-2010-06-290668.
74. Bryce A.H., Ketterling R., Gertz M.A., et al. Association of translocation t(11;14) with survival in patients with light chain (AL) amyloidosis. J Clin Oncol 2008, 26. (2008 (May 20 Suppl.) abstr 8549).
75. Bochtler T., Hegenbart U., Cremer F.W., et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008, 111(9):4700-4705.
76. Zhou P., Hoffman J., Landau H., Hassoun H., Iyer L., Comenzo R.L. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk 2011, 12:49-58.
77. Gertz M., Lacy M., Dispenzieri A., et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008, 49(1):36-41.
78. Gertz M.A., Kyle R.A., Greipp P.R. Response rates and survival in primary systemic amyloidosis. Blood 1991, 77(2):257-262.
79. Moreau P., Leblond V., Bourquelot P., et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998, 101(4):766-769.
80. Gertz M.A., Lacy M.Q., Dispenzieri A., Hayman S.R., Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007, 19(2):136-141.
81. Gertz M.A., Kyle R.A., Greipp P.R. Hyposplenism in primary systemic amyloidosis. Ann Intern Med 1983, 98(4):475-477.
82. Gertz M.A., Kyle R.A., Greipp P.R., Katzmann J.A., O'Fallon W.M. Beta 2-microglobulin predicts survival in primary systemic amyloidosis. Am J Med 1990, 89(5):609-614.
83. Pardanani A., Witzig T.E., Schroeder G., et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003, 101(3):827-830.
84. Hazenberg B.P., van Rijswijk M.H., Lub-de Hooge M.N., et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007, 48(6):865-872.
85. Hachulla E., Maulin L., Deveaux M., et al. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Am J Med 1996, 101(1):77-87.
86. Kumar S., Dispenzieri A., Lacy M.Q., et al. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc 2008, 83(3):297-303.
87. Gertz M.A., Comenzo R., Falk R.H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005, 79(4):319-328.
88. Lachmann H.J., Gallimore R., Gillmore J.D., et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003, 122(1):78-84.
89. Sanchorawala V., Seldin D.C., Magnani B., Skinner M., Wright D.G. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005, 36(7):597-600.
90. Comenzo R.L., Vosburgh E., Falk R.H., et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91(10):3662-3670.
91. Kyle R.A., Gertz M.A., Greipp P.R., et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336(17):1202-1207.
92. Kastritis E., Wechalekar A.D., Dimopoulos M.A., et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010, 28(6):1031-1037.
93. Palladini G., Perfetti V., Obici L., et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103(8):2936-2938.
94. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140(2):85-93.
95. Palladini G., Dispenzieri A., Gertz M.A., et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010, 116(11):1364-
96. Kumar S.K., Dispenzieri A., Lacy M.Q., et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011, 86(3):251-255. Prepublished on 2011/02/18 as DOI 10.1002/ajh.21948.
97. Pinney J.H., Lachmann H.J., Bansi L., et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 2011, 29(6):674-681. Prepublished on 2011/01/12 as DOI 10.1200/JCO.2010.30.5235.
98. Merlini G., Seldin D.C., Gertz M.A. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011, 29(14):1924-1933. Prepublished on 2011/04/13 as DOI 10.1200/JCO.2010.32.2271.
99. Dispenzieri A., Dingli D., Kumar S.K., et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010, 85(10):757-759.
100. Palladini G., Russo P., Foli A., et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2012, 91:89-92.
101. Tapan U., Seldin D.C., Finn K.T., et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 2010, 116(23):5071-5072. Prepublished on 2010/12/04 as DOI 10.1182/blood-2010-09-305136.
102. Gibbs S.D.J., De Cruz M., Sattianayagam P.T., et al. Transient post chemotherapy rise in NT Pro-BNP in AL amyloidosis: implications for organ response assessment. ASH Annu Meet Abstr 2009, 114(22):1791.
103. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007, 92(10):1415-1418.
104. Gertz M.A., Lacy M.Q., Lust J.A., Greipp P.R., Witzig T.E., Kyle R.A. Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica 2008, 93(9):1402-1406. Prepublished on 2008/07/22 as DOI 10.3324/haematol.12982.
105. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357(11):1083-1093.
106. Sanchorawala V., Skinner M., Quillen K., Finn K.T., Doros G., Seldin D.C. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007, 110(10):3561-3563.
107. Palladini G., Russo P., Nuvolone M., et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007, 110(2):787-788.
108. Cohen A.D., Zhou P., Chou J., et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone+/-thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007, 139(2):224-233. Prepublished on 2007/09/28 as DOI 10.1111/j.1365-2141.2007.06783.x.
109. Landau H., Hassoun H., Bello C., et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2011, 18(Suppl. 1):130-131. Prepublished on 2011/08/16 as DOI 10.3109/13506129.2011.574354050.
110. Trinkaus-Randall V., Walsh M.T., Steeves S., Monis G., Connors L.H., Skinner M. Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol 2005, 166(1):197-208.
111. Pepys M.B., Herbert J., Hutchinson W.L., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417(6886):254-259.
112. Bodin K., Ellmerich S., Kahan M.C., et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010, 468(7320):93-97.
113. Wall J.S., Kennel S.J., Stuckey A.C., et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010, 116(13):2241-2244. Prepublished on 2010/06/05 as DOI 10.1182/blood-2010-03-273797.
114. Deshmukh M., Elderfield K., Rahemtulla A., Naresh K.N. Immunophenotype of neoplastic plasma cells in AL amyloidosis. J Clin Pathol 2009, 62(8):724-730.
115. Zhou P., Comenzo R.L., Olshen A.B., et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008, 111(7):3403-3406. Prepublished on 2008/01/25 as DOI 10.1182/blood-2007-11-125526.
116. Zhou P., Teruya-Feldstein J., Lu P., Fleisher M., Olshen A., Comenzo R.L. Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood 2008, 111(2):549-557.
117. Phipps J.E., Kestler D.P., Foster J.S., et al. Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol 2010, 38(11):1006-1013. Prepublished on 2010/07/20 as DOI 10.1016/j.exphem.2010.07.001.
118. Jones N.F., Hilton P.J., Tighe J.R., Hobbs J.R. Treatment of "primary" renal amyloidosis with melphalan. Lancet 1972, 2(7778):616-619.
119. Cohen H.J., Lessin L.S., Hallal J., Burkholder P. Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome. Ann Intern Med 1975, 82(4):466-473.
120. Kyle R.A., Greipp P.R., Garton J.P., Gertz M.A. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 1985, 79(6):708-716.
121. Kyle R.A., Greipp P.R. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 1978, 52(4):818-827.
122. Skinner M., Anderson J., Simms R., et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996, 100(3):290-298.
123. Gertz M.A., Lacy M.Q., Lust J.A., Greipp P.R., Witzig T.E., Kyle R.A. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol 1999, 61(2):115-119.
124. Gertz M.A., Lacy M.Q., Lust J.A., Greipp P.R., Witzig T.E., Kyle R.A. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999, 16(2):104-109.
125. Dhodapkar M.V., Hussein M.A., Rasmussen E., et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004, 104(12):3520-3526.
126. Levy Y., Belghiti-Deprez D., Sobel A. Treatment of AL amyloidosis without myeloma. Ann Med Interne (Paris) 1988, 139(3):190-193.
127. Wardley A.M., Jayson G.C., Goldsmith D.J., Venning M.C., Ackrill P., Scarffe J.H. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 1998, 78(6):774-776.
128. van Gameren I., Hazenberg B.P., Jager P.L., Smit J.W., Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002, 9(3):165-174.
129. Ichida M., Imagawa S., Ohmine K., et al. Successful treatment of multiple myeloma-associated amyloidosis by interferon-alpha, dimethyl sulfoxide, and VAD (vincristine, adriamycin, and dexamethasone). Int J Hematol 2000, 72(4):491-493.
130. Gono T., Matsuda M., Shimojima Y., et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 2004, 11(4):245-256.
131. Gertz M.A., Lacy M.Q., Lust J.A., Greipp P.R., Witzig T.E., Kyle R.A. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999, 17(1):262-267.
132. Dietrich S., Schonland S.O., Benner A., et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010, 116(4):522-528. Prepublished on 2010/04/09 as DOI 10.1182/blood-2009-11-253237.
133. Dispenzieri A., Lacy M.Q., Kyle R.A., et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001, 19(14):3350-3356. Prepublished on 2001/07/17 as DOI.
134. Gertz M.A., Kyle R.A. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 1990, 150(3):629-633.
135. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004, 34(12):1025-1031.
136. Moreau P., Milpied N., de Faucal P., et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996, 87(7):3063-3064.
137. Vesole D.H., Perez W.S., Akasheh M., Boudreau C., Reece D.E., Bredeson C.N. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006, 81(7):880-888.
138. Cibeira M.T., Sanchorawala V., Seldin D.C., et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011, 118(16):4346-4352. Prepublished on 2011/08/11 as DOI 10.1182/blood-2011-01-330738.
139. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 2011, 46(7):970-975. Prepublished on 2010/10/12 as DOI 10.1038/bmt.2010.234.
140. Sanchorawala V., Quillen K., Sloan J.M., Andrea N.T., Seldin D.C. Bortezomib and high dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica 2011, 96:1890-1892.
141. Sanchorawala V., Wright D.G., Seldin D.C., et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004, 33(4):381-388.
142. Schonland S.O., Lokhorst H., Buzyn A., et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006, 107(6):2578-2584.
143. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004, 103(10):3960-3963.
144. Seldin D.C., Choufani E.B., Dember L.M., et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003, 3(4):241-246.
145. Dispenzieri A., Lacy M.Q., Geyer S.M., et al. Low dose single agent thalidomide is tolerated in patients with primary systemic amyloidosis, but responses are limited. ASH Annu Meet Abstr 2004, 104(11):4920.
146. Palladini G., Perfetti V., Perlini S., et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005, 105(7):2949-2951.
147. Wechalekar A.D., Goodman H.J., Lachmann H.J., Offer M., Hawkins P.N., Gillmore J.D. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007, 109(2):457-464.
148. Gillmore J., Cocks K., Gibbs S.D.J., et al. Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic AL amyloidosis-results from the UK Amyloidosis Treatment Trial. ASH Annu Meet Abstr 2009, 114(22):2869.
149. Palladini G., Russo P., Lavatelli F., et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009, 88(4):347-350.
150. Specter R., Sanchorawala V., Seldin D.C., et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011, 26(3):881-886. Prepublished on 2010/08/10 as DOI 10.1093/ndt/gfq482.
151. Dispenzieri A., Lacy M.Q., Zeldenrust S.R., et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007, 109(2):465-470.
152. Sanchorawala V., Wright D.G., Rosenzweig M., et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007, 109(2):492-496.
153. Sanchorawala V., Finn K.T., Fennessey S., et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 2010, 116(11):1990-1991.
154. Moreau P., Jaccard A., Benboubker L., et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010, 116(23):4777-4782.
155. Palladini G., Russo P., Bragotti L.Z., et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis. ASH Annu Meet Abstr 2009, 114(22):2863.
156. Kumar S., Hayman S.R., Buadi F., et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. ASH Annu Meet Abstr 2009, 114(22):3853.
157. Dispenzieri A., Gertz M.A.A., Hayman S.R., et al. A phase-2 study of pomalidomide and dexamethasone in previously-treated light-chain (AL) amyloidosis. ASH Annu Meet Abstr 2010, 116(21):987.
158. Reece D.E., Hegenbart U., Sanchorawala V., et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011, 118(4):865-873. Prepublished on 2011/05/13 as DOI 10.1182/blood-2011-02-334227.
159. Reece D.E., Sanchorawala V., Hegenbart U., et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009, 114(8):1489-1497.
160. Gasparetto C., Sanchorawala V., Snyder R.M., et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. J Clin Oncol (Meet Abstr) 2010, 28(15_Suppl.):8024.
161. Mikhael J.R., Schuster S.R., Jimenez-Zepeda V.H., et al. The combination of cyclophosphamide-bortezomib-dexamethasone (CYBOR-D) is a highly effective and well tolerated regimen that produces rapid and complete hematological response in patients with AL amyloidosis. ASH Annu Meet Abstr 2010, 116(21):3063.
162. Berk J.L., Keane J., Seldin D.C., et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003, 124(3):969-977. Prepublished on 2003/09/13 as DOI.
163. Dubrey S., Pollak A., Skinner M., Falk R.H. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 1995, 74(5):541-544.
164. Feng D., Syed I.S., Martinez M., et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009, 119(18):2490-2497.
165. Rubinow A., Skinner M., Cohen A.S. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981, 63(6):1285-1288.
166. Gertz M.A., Falk R.H., Skinner M., Cohen A.S., Kyle R.A. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985, 55(13 Pt. 1):1645.
167. Kristen A.V., Dengler T.J., Hegenbart U., et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008, 5(2):235-240.
168. Lin G., Dispenzieri A., Brady P.A. Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 2010, 31(12):1538. Prepublished on 2010/01/12 as DOI 10.1093/eurheartj/ehp592.
169. Dhoble A., Khasnis A., Olomu A., Thakur R. Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol 2009, 32(8):E63-E65. Prepublished on 2009/05/21 as DOI 10.1002/clc.20389.
170. Yaoita H., Iwai-Takano M., Ogawa K., et al. Attenuation of diastolic heart failure and life-threatening ventricular tachyarrhythmia after peripheral blood stem cell transplantation combined with cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis. Circ J 2008, 72(2):331-334.
171. Bergesio F., Ciciani A.M., Manganaro M., et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 2008, 23(3):941-951.
172. Gertz M.A., Kyle R.A., O'Fallon W.M. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med 1992, 152(11):2245-2250.
173. Singer W., Sandroni P., Opfer-Gehrking T.L., et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006, 63(4):513-518.
174. Dubrey S.W., Burke M.M., Hawkins P.N., Banner N.R. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004, 23(10):1142-1153. Prepublished on 2004/10/13 as DOI 10.1016/j.healun.2003.08.027.
175. Lacy M.Q., Dispenzieri A., Hayman S.R., et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant 2008, 27(8):823-829. Prepublished on 2008/07/29 as DOI 10.1016/j.healun.2008.05.016.
176. Dey B.R., Chung S.S., Spitzer T.R., et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 2010, 90(8):905-911. Prepublished on 2010/08/25 as DOI 10.1097/TP.0b013e3181f10edb.
177. Hosenpud J.D., Uretsky B.F., Griffith B.P., O'Connell J.B., Olivari M.T., Valantine H.A. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Transplant 1990, 9(4):346-350.
178. Hosenpud J.D., DeMarco T., Frazier O.H., et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 1991, 84(5 Suppl.):III338-III343.
179. Sattianayagam P.T., Gibbs S.D., Pinney J.H., et al. Solid organ transplantation in AL amyloidosis. Am J Transplant 2010, 10(9):2124-2131.
180. Gillmore J.D., Goodman H.J., Lachmann H.J., et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006, 107(3):1227-1229. Prepublished on 2005/10/08 as DOI 10.1182/blood-2005-08-3253.
181. Kpodonu J., Massad M.G., Caines A., Geha A.S. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005, 24(11):1763-1765. Prepublished on 2005/11/22 as DOI 10.1016/j.healun.2004.08.025.
182. Mignot A., Varnous S., Redonnet M., et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 2008, 101(9):523-532. Prepublished on 2008/12/02 as DOI 10.1016/j.acvd.2008.06.018.
183. Kristen A.V., Sack F.-U., Schonland S.O., et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail 2009, 11(10):1014-1020. 10.1093/eurjhf/hfp121.
184. Roig E., Almenar L., Gonzalez-Vilchez F., et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry for heart transplantation. Am J Transplant 2009, 9(6):1414-1419.
185. Thaunat O., Alyanakian M.A., Varnous S., et al. Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis. Bone Marrow Transplant 2005, 35(4):419-420. Prepublished on 2005/01/11 as DOI 10.1038/sj.bmt.1704772.
186. Herrmann S.M., Gertz M.A., Stegall M.D., et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 2011, 26(6):2032-2036. Prepublished on 2011/05/06 as DOI 10.1093/ndt/gfr067.
187. Casserly L.F., Fadia A., Sanchorawala V., et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003, 63(3):1051-1057.
188. Nowak G., Westermark P., Wernerson A., Herlenius G., Sletten K., Ericzon B.G. Liver transplantation as rescue treatment in a patient with primary AL kappa amyloidosis. Transpl Int 2000, 13(2):92-97. Prepublished on 2000/06/03 as DOI.
189. Utz J.P., Gertz M.A., Kalra S. External-beam radiation therapy in the treatment of diffuse tracheobronchial amyloidosis. Chest 2001, 120(5):1735-1738.
190. Pitz M.W., Gibson I.W., Johnston J.B. Isolated pulmonary amyloidosis: case report and review of the literature. Am J Hematol 2006, 81(3):212-213.
191. Dundore P.A., Aisner S.C., Templeton P.A., Krasna M.J., White C.S., Seidman J.D. Nodular pulmonary amyloidosis: diagnosis by fine-needle aspiration cytology and a review of the literature. Diagn Cytopathol 1993, 9(5):562-564.
192. Neben-Wittich M.A., Foote R.L., Kalra S. External beam radiation therapy for tracheobronchial amyloidosis. Chest 2007, 132(1):262-267.
193. Mariani A.J., Barrett D.M., Kurtz S.B., Kyle R.A. Bilateral localized amyloidosis of the ureter presenting with anuria. J Urol 1978, 120(6):757-759.
194. Shittu O.B., Weston P.M. Localised amyloidosis of the urinary bladder: a case report and review of treatment. West Afr J Med 1994, 13(4):252-253.
195. Malek R.S., Wahner-Roedler D.L., Gertz M.A., Kyle R.A. Primary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy. J Urol 2002, 168(3):1018-1020.
196. Dispenzieri A., Lacy M.Q., Rajkumar S.V., et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003, 10(4):257-261.
197. Comenzo R.L., Reece D., Palladini G., et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia: official journal of the Leukemia Society of America 2012, Leukemia Research Fund, UK.